Get the Stockscreener App
1.27
5.83%
0.07
Standard Biotools Inc stock is traded at $1.27, with a volume of 2.07M.
It is up +5.83% in the last 24 hours and down -6.62% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
2.07M
Relative Volume:
1.17
Market Cap:
$482.37M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-1.3368
EPS:
-0.95
Net Cash Flow:
$-46.12M
1W Performance:
+3.25%
1M Performance:
-6.62%
6M Performance:
-2.31%
1Y Performance:
-34.87%
1-Day Range:
$1.19
$1.285
1-Week Range:
$1.19
$1.32
52-Week Range:
$0.92
$2.32
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
2 TOWER PLACE, SOUTH SAN FRANCISCO
Compare LAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.27 | 485.13M | 106.34M | -74.66M | -46.12M | -0.95 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates - MSN
Standard Biotools Inc. Faces Challenges in SomaScan Divestiture: Potential Risks and Strategic Imperatives - MSN
Standard BioTools Inc. Stock Lags Behind Sector Benchmarks2025 Price Momentum & Verified Technical Signals - newsimpact.co.kr
Standard Biotools Inc. Faces Divestiture Risks: Management Distraction and Financial Impacts - AInvest
What makes Standard BioTools Inc. stock price move sharply2025 Geopolitical Influence & Weekly Top Gainers Trade List - classian.co.kr
Is Standard BioTools Inc. forming bullish engulfing patternsMarket Weekly Review & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina - ADVFN Brasil
Standard BioTools Delays Quarterly Report Filing - MSN
Standard BioTools 2025 Q2 Earnings Losses Narrow by 26.8% - AInvest
Casdin funds buys Standard Biotools (LAB) shares worth $443,032 By Investing.com - Investing.com Nigeria
Casdin funds buys Standard Biotools (LAB) shares worth $443,032 - Investing.com
STANDARD BIOTOOLS INC. SEC 10-Q Report - TradingView
Standard BioTools Reports Q2 2025 Financial Results - TipRanks
TD Cowen Downgrades Standard BioTools to Hold From Buy, $1.60 Price Target - MarketScreener
Standard BioTools Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Hold Rating for Standard BioTools Amid Uncertainty Following SomaLogic Sale and Market Challenges - TipRanks
Can Traders Expect Breakout From Standard BioTools Inc. This Week [Sell Signal]Free Weekly Breakout Stock Alerts - 선데이타임즈
Standard BioTools stock holds Sector Weight rating at KeyBanc amid M&A potential - Investing.com Nigeria
KeyBanc Maintains Standard BioTools(LAB.US) With Hold Rating - 富途牛牛
Standard BioTools: Q2 Earnings Snapshot - New Haven Register
Standard BioTools Reports Q2 Loss, Tops Revenue Estimates - AInvest
Standard BioTools Expects FY25 Revenue of $165M-$175M - AInvest
Standard BioTools Steadies Revenue Despite Tough Market Headwinds - Finimize
Standard BioTools Q2 rev. $42mln, SomaLogic sold to Illumina for up to $425mln. - AInvest
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Standard Biotools earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Standard BioTools Q2 revenue dips 3% - MarketScreener
Standard BioTools Reports Second Quarter 2025 Financial Results - The Manila Times
Standard BioTools' Five-Year Share Price Down 84%, Revenue Growth of 3.1% - AInvest
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable - Yahoo Finance
Standard BioTools LAB Q2 2025 Earnings Preview Upside Potential on Strategic Expansion - AInvest
Standard BioTools Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Standard BioTools Q2 2025 Earnings Preview - MSN
Standard BioTools Q2 2025 Earnings Outlook: Strategic Shifts, Revenue Pressures, and the Path to Value Creation - AInvest
What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings - Yahoo Finance
Standard BioTools Partners with Precision Health in Singapore for Proteomic Collaboration - AInvest
Standard BioTools and Precision Health Research, Singapore - GlobeNewswire
Major Win: Standard BioTools Secures 100,000-Sample Singapore Biobank Deal for Population Health Study - Stock Titan
Why is Standard BioTools Inc. stock attracting strong analyst attentionUnlock daily stock market insights for success - Jammu Links News
How volatile is Standard BioTools Inc. stock compared to the marketInvest smarter with daily market updates - Jammu Links News
Is Standard BioTools Inc. a growth stock or a value stockBuild wealth with steady, reliable stocks - Jammu Links News
What analysts say about Standard BioTools Inc. stockInvest confidently with data-backed picks - Jammu Links News
How many analysts rate Standard BioTools Inc. as a “Buy”Maximize returns with effective portfolio management - Jammu Links News
What institutional investors are buying Standard BioTools Inc. stockDiscover stocks with explosive potential - Jammu Links News
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Standard Biotools Inc Stock (LAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Casdin Partners Master Fund, L | Director |
Aug 14 '25 |
Buy |
1.21 |
133,220 |
161,543 |
59,600,000 |
| Casdin Partners Master Fund, L | Director |
Aug 13 '25 |
Buy |
1.31 |
75,000 |
98,280 |
59,466,780 |
| Kim Hanjoon Alex | Chief Financial Officer |
May 23 '25 |
Sale |
0.94 |
1,428 |
1,344 |
930,286 |
| Mackay Sean | SVP & Chief Business Officer |
May 23 '25 |
Sale |
0.94 |
13,217 |
12,437 |
843,076 |
| Egholm Michael | President & CEO |
May 23 '25 |
Sale |
0.94 |
5,473 |
5,150 |
2,741,191 |
| Kim Hanjoon Alex | Chief Financial Officer |
May 22 '25 |
Sale |
1.00 |
1,355 |
1,358 |
931,714 |
| Egholm Michael | President & CEO |
May 22 '25 |
Sale |
1.00 |
5,116 |
5,126 |
2,746,664 |
| Mackay Sean | SVP & Chief Business Officer |
May 21 '25 |
Sale |
1.03 |
12,838 |
13,223 |
868,829 |
| Mackay Sean | SVP & Chief Business Officer |
May 22 '25 |
Sale |
1.00 |
12,536 |
12,561 |
856,293 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):